WuXi Biologics Reports Solid 2024 Interim Results

Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7% Added 61 new integrated projects, including 4 from late-phase and commercial stage Client's molecule recently acquired by MNC, highlighting a potential best-in-class CD3 asset utilizing three of our proprietary technology platforms Total integrated projects of 742, one of the largest portfolios of complex biologics Successful EMA inspections of 13 ...